- Home
- NVX vs PBYI Comparison
NVX vs PBYI Comparison
Compare NVX & PBYI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NVX
- PBYI
- Stock Information
- Founded
- NVX 2012
- PBYI 2010
- Country
- NVX Australia
- PBYI United States
- Employees
- NVX N/A
- PBYI N/A
- Industry
- NVX Industrial Machinery/Components
- PBYI Biotechnology: Pharmaceutical Preparations
- Sector
- NVX Miscellaneous
- PBYI Health Care
- Exchange
- NVX Nasdaq
- PBYI Nasdaq
- Market Cap
- NVX 176.8M
- PBYI 171.7M
- IPO Year
- NVX N/A
- PBYI N/A
- Fundamental
- Price
- NVX $1.43
- PBYI $5.25
- Analyst Decision
- NVX
- PBYI Strong Buy
- Analyst Count
- NVX 0
- PBYI 1
- Target Price
- NVX N/A
- PBYI $7.00
- AVG Volume (30 Days)
- NVX 167.4K
- PBYI 910.5K
- Earning Date
- NVX 01-01-0001
- PBYI 08-07-2025
- Dividend Yield
- NVX N/A
- PBYI N/A
- EPS Growth
- NVX N/A
- PBYI 434.29
- EPS
- NVX N/A
- PBYI 0.97
- Revenue
- NVX $5,931,433.00
- PBYI $238,062,000.00
- Revenue This Year
- NVX $135.22
- PBYI N/A
- Revenue Next Year
- NVX $1,647.66
- PBYI N/A
- P/E Ratio
- NVX N/A
- PBYI $5.39
- Revenue Growth
- NVX N/A
- PBYI 8.63
- 52 Week Low
- NVX $0.81
- PBYI $2.23
- 52 Week High
- NVX $2.73
- PBYI $6.07
- Technical
- Relative Strength Index (RSI)
- NVX 57.90
- PBYI 70.56
- Support Level
- NVX $1.14
- PBYI $4.81
- Resistance Level
- NVX $1.36
- PBYI $5.40
- Average True Range (ATR)
- NVX 0.09
- PBYI 0.49
- MACD
- NVX 0.00
- PBYI 0.10
- Stochastic Oscillator
- NVX 92.48
- PBYI 72.85
About NVX NOVONIX Limited American Depository Shares
NOVONIX Ltd operates in the lithium-ion battery industry. The company has three operating segments namely Graphite Exploration, Battery Technology, and Battery Materials. Graphite Exploration segment is engaged in the exploration and development of high-grade flake graphite deposits. The Battery Technology segment develops battery cell testing equipment and carries out research and development in battery development. The Battery Materials segment develops and manufactures battery anode materials. The Battery Technology segment generates maximum revenue for the company.
About PBYI Puma Biotechnology Inc
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes inventive products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis resulting into apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.